<SEC-DOCUMENT>0001193125-18-311307.txt : 20181030
<SEC-HEADER>0001193125-18-311307.hdr.sgml : 20181030
<ACCEPTANCE-DATETIME>20181030080100
ACCESSION NUMBER:		0001193125-18-311307
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181030
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181030
DATE AS OF CHANGE:		20181030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		181145554

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d646661d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;30, 2018, Japan Standard Time </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
<FONT STYLE="white-space:nowrap">(17&nbsp;CFR&nbsp;240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act <FONT STYLE="white-space:nowrap">(17&nbsp;CFR&nbsp;240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act <FONT STYLE="white-space:nowrap">(17&nbsp;CFR&nbsp;240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2018, Japan Standard Time, FibroGen, Inc. and its collaboration partner, Astellas Pharma Inc., issued a press release in
which they announced the presentation of data at the American Society Nephrology Kidney Week 2018 from Phase&nbsp;3 studies conducted in Japan of roxadustat for the treatment of anemia associated with chronic kidney disease in patients on dialysis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d646661dex991.htm">Press Release titled &#147;ASN Kidney Week 2018: Data Presented from Two Japanese Phase&nbsp;
3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis&#148; dated October&nbsp;30, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: October&nbsp;30, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d646661dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g646661g98y34.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g646661g71e91.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Press Release </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASN Kidney Week 2018: Data Presented from </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Two Japanese Phase 3 Studies on Roxadustat in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Treatment of Anemia Associated with </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chronic Kidney Disease in Patients on Dialysis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TOKYO and San Francisco, October</B><B></B><B>&nbsp;30, 2018</B> - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,
&#147;Astellas&#148;) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, &#147;FibroGen&#148;) today announced the presentation of data from two Japanese Phase 3 studies
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(1517-CL-0302</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1517-CL-0307)</FONT></FONT> of roxadustat (development code: <FONT
STYLE="white-space:nowrap">ASP1517/FG-4592)</FONT> for the treatment of anemia associated with Chronic Kidney Disease (CKD) in patients on dialysis at the American Society of Nephrology (ASN) Kidney Week 2018 that was held October&nbsp;23 &#150; 28,
2018 in San Diego, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1517-CL-0302</FONT></FONT> study evaluated the
efficacy and safety of roxadustat in Japanese CKD patients on peritoneal dialysis (PD). In this study, roxadustat was well tolerated and achieved and maintained hemoglobin (Hb) levels within the target range in Japanese CKD patients on PD, with or
without previous treatment with erythropoiesis-stimulating agents (ESAs). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1517-CL-0307</FONT></FONT> study evaluated the efficacy and safety of roxadustat compared to darbepoetin
alfa (genetical recombination) (&#147;darbepoetin alfa&#148;) in the treatment of CKD anemia in patients on hemodialysis (HD) who had previously been treated with recombinant human erythropoietin (rHuEPO) or darbepoetin alfa. In this study,
roxadustat effectively maintained Hb within the range of <FONT STYLE="white-space:nowrap">10-12</FONT> g/dL in HD patients, and its efficacy was <FONT STYLE="white-space:nowrap">non-inferior</FONT> to darbepoetin alfa. In both studies, the safety
profile of roxadustat was consistent with previous studies in the CKD population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Anemia, a common complication of CKD, is associated with
significant morbidity and mortality, and the condition can have a debilitating impact on the patients affected,&#148; said Salim Mujais, M.D., senior vice president and global therapeutic area head, Medical Specialties Development, Astellas.
&#147;The presented data from two Phase 3 studies conducted in Japanese patients, showing roxadustat to be well tolerated and efficacious, support the potential of roxadustat as a new oral therapeutic option for CKD patients with anemia, including
those on HD and on PD. We look forward to continuing to advance the development of roxadustat and contributing to a treatment of anemia associated with CKD.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are highlights of key data from these two Phase 3 studies of roxadustat: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1517-CL-0302</FONT></FONT> study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title: Phase 3, Multicenter, Open-Label Study of Intermittent Oral Roxadustat in Peritoneal Dialysis CKD Patients with Anemia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Publication #: <FONT STYLE="white-space:nowrap">SA-OR075,</FONT> Oral abstract session on Saturday, October&nbsp;27 from 5:54 p.m. to 6:06 p.m. PT at San
Diego Convention Center, Room 2) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Study design </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This multicenter <FONT STYLE="white-space:nowrap">24-week,</FONT> randomized, open-label Phase 3 study enrolled
Japanese CKD patients on PD with anemia in two groups based on prior ESA treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients not previously treated with ESA (ESA Naive) were randomized to roxadustat 50 mg or 70 mg; patients
previously treated with ESA (ESA Conversion) were switched to roxadustat 70 mg or 100 mg depending on prior ESA dose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dose was adjusted throughout the study to maintain the Hb levels at a target range of <FONT
STYLE="white-space:nowrap">10-12</FONT> g/dL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efficacy endpoints were maintenance rate of target Hb level at Weeks
<FONT STYLE="white-space:nowrap">18-24,</FONT> cumulative response rate at the end of treatment (two Hb thresholds, 10.0 g/dL and 10.5 g/dL; and Hb increase, <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1.0 g/dL), average Hb levels at Weeks <FONT
STYLE="white-space:nowrap">18-24</FONT> and its change from baseline, and rate of rise in Hb levels from Week 0 to Week 4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Safety was assessed by occurrence of Adverse Events (AEs). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Study results </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">56 patients were enrolled (13 ESA Naive; 43 ESA Conversion). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efficacy endpoints: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hb maintenance rates were 92.3% (95% CI: 64.0, 99.8; ESA Naive) and 74.4% (95% CI: 58.8, 86.5; ESA Conversion).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintenance rates of patients with at least one Hb value at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT>
were 92.3% (95% CI: 64.0, 99.8; ESA Naive) and 86.5% (95% CI: 71.2, 95.5; ESA Conversion). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the ESA Naive Group, cumulative response rate for both Hb thresholds was 100.0%. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mean of average Hb levels at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT> were 11.05 g/dL (95% CI:
10.67, 11.42; ESA Naive) and 10.93 g/dL (95% CI: 10.73, 11.13; ESA Conversion). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mean change in average Hb at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT> from baseline was 1.69 g/dL
(95% CI: 1.06, 2.33; ESA Naive) and 0.14 g/dL (95% CI: <FONT STYLE="white-space:nowrap">-0.12,</FONT> 0.39; ESA Conversion). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the ESA Naive Group, mean (SD) rate of rise in Hb levels from Week 0 to Week 4 was 0.193 (0.203) and 0.556
(0.408) g/dL/week with roxadustat 50 mg and 70 mg, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The most common treatment emergent adverse events (TEAEs) were nasopharyngitis, back pain, catheter site
infection, diarrhea, vomiting, abdominal pain, conjunctivitis, constipation, nausea, and pruritus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1517-CL-0307</FONT></FONT> study
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title: Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Conversion Study of Oral Roxadustat in CKD Patients with Anemia on
Hemodialysis in Japan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Publication #: <FONT STYLE="white-space:nowrap">TH-PO1151,</FONT> Poster session on Thursday, October&nbsp;25 from 10:00 a.m.
to 12:00 noon PT at Exhibit hall) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Study design </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This multicenter, <FONT STYLE="white-space:nowrap">24-week,</FONT> randomized, double-blind, double-dummy,
darbepoetin-controlled Phase 3 study enrolled Japanese CKD patients on HD for <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>12 weeks, with anemia converted from rHuEPO or darbepoetin alpha to roxadustat. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients were randomized to roxadustat (70 mg and 100 mg) three times weekly or darbepoetin alfa <FONT
STYLE="white-space:nowrap">(10-60</FONT> <FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g) once weekly; roxadustat dose was adjusted to maintain Hb between 10 and12 g/dL. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Primary endpoint was the change of average Hb levels from baseline to Weeks
<FONT STYLE="white-space:nowrap">18-24.</FONT> Roxadustat efficacy was confirmed if the 95% CI of average Hb at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT> was within the range of <FONT STYLE="white-space:nowrap">10-12</FONT> g/dL. <FONT
STYLE="white-space:nowrap">Non-inferiority</FONT> to darbepoetin alfa was confirmed if the lower limit of the 95% CI of the difference in the means of change of average Hb levels from baseline to Weeks <FONT STYLE="white-space:nowrap">18-24</FONT>
between roxadustat and darbepoetin alfa was above <FONT STYLE="white-space:nowrap">-0.75</FONT> g/dL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Secondary endpoints included: average Hb levels of Weeks <FONT STYLE="white-space:nowrap">18-24,</FONT>
proportion of patients who achieved an average Hb level of <FONT STYLE="white-space:nowrap">10-12</FONT> g/dL at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT> (maintenance rate), and iron parameters (i.e., serum iron, ferritin, Transferrin
Saturation (TSAT), transferrin, and Total Iron Binding Capacity (TIBC)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Safety was assessed as occurrence of AEs and ophthalmological examination (color fundus photography and optical
coherence tomography (OCT)). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Study results </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">303 patients were randomized to roxadustat (n=151) or darbepoetin alfa (n=152). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mean average Hb at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT> was 10.99 g/dL (95% CI: 10.88, 11.10)
with roxadustat, confirming its efficacy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The difference between roxadustat and darbepoetin alfa in change of average Hb levels from baseline to Weeks <FONT
STYLE="white-space:nowrap">18-24</FONT> was <FONT STYLE="white-space:nowrap">-0.02</FONT> g/dL (95% CI: <FONT STYLE="white-space:nowrap">-0.18,</FONT> 0.15), confirming <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of roxadustat efficacy
to darbepoetin alfa. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hb maintenance rates were 79.3% (95% CI: 72.0, 85.5; roxadustat) and 83.4% (95% CI: 76.5, 89.0; darbepoetin
alfa). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The proportion of patients with at least one Hb value maintained at Hb
<FONT STYLE="white-space:nowrap">10-12</FONT> g/dL at Weeks <FONT STYLE="white-space:nowrap">18-24</FONT> were 95.2% (95% CI: 89.8, 98.2; roxadustat) and 91.3% (95% CI: 85.3, 95.4; darbepoetin alfa). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Among patients taking roxadustat, serum iron, ferritin, and TSAT were clinically stable; and transferrin and TIBC
increased through Week 4 and then remained stable. No remarkable changes in iron parameters occurred with darbepoetin alfa. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The most common TEAEs in both groups were nasopharyngitis, shunt stenosis, diarrhea, contusion, and vomiting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In ophthalmology evaluations, blinded review of color fundus photography images revealed new or worsening retinal
hemorrhage occurred in 32.4% of patients receiving roxadustat and 36.6% of patients receiving darbepoetin alfa during treatment; no clinically meaningful changes in retinal thickness evaluated with OCT were observed from Week 0 through end of
treatment in either of the treatment groups. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No increased risk of ophthalmological abnormalities including retinal hemorrhages were observed in patients
treated with roxadustat compared to darbepoetin alfa. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roxadustat was well tolerated with a safety profile similar to that of darbepoetin alfa and consistent with
previous reports. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about roxadustat studies, please visit to clinicaltrials.gov at: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Chronic Kidney Disease (CKD) and Anemia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CKD is
estimated to affect more than 200&nbsp;million people worldwide*<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> and specifically in Japan, the prevalence of CKD has increased significantly over time.*<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP> Although CKD can occur at any age, it becomes more common in aging populations, and the prevalence is increasing. Anemia is a common complication of CKD and is associated with significant morbidity
and mortality in dialysis and <FONT STYLE="white-space:nowrap">non-dialysis</FONT> populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large
and growing unmet medical need. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat, discovered and developed by FibroGen, is a compound currently in Phase 3 development on a global basis as a potential therapy for anemia associated
with CKD in both patients on dialysis and not on dialysis. Roxadustat is an orally administered small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase activity. HIF is a protein transcription factor that induces the natural
physiological response to conditions of low oxygen, &#147;turning on&#148; erythropoiesis (the process by which red blood cells are produced). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas
and FibroGen are collaborating on the development of roxadustat for the potential treatment of anemia in patients with CKD and myelodysplastic syndromes in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East,
and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in patients with CKD in the U.S., China, and other markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat is currently in Phase 3 clinical development for the treatment of anemia associated with myelodysplastic syndromes (MDS) in the U.S. and in Phase
2/3 development for MDS in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information about roxadustat studies, please visit clinicaltrials.gov at this link: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</U>. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ojo, A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research.
<I>Transactions of the American Clinical and Climatological Association</I>. 2014, No.&nbsp;125, p. <FONT STYLE="white-space:nowrap">229-246.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. <I>Nephrol Dial
Transplan</I>t. 2010, Aug, vol. 25, no.8, 2557-2564. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Astellas </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and
reliable pharmaceutical products. For more information, please visit our website at <U>https://www.astellas.com/en</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and
developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth
factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF
prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review by the State Drug Administration (SDA). Roxadustat
is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3
clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase&nbsp;2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more
information, please visit <U>www.fibrogen.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Astellas Cautionary Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are
forward-looking statements about the future performance of Astellas. These statements are based on management&#146;s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and
uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i)&nbsp;changes in general economic conditions and in laws and
regulations, relating to pharmaceutical markets, (ii)&nbsp;currency exchange rate fluctuations, (iii)&nbsp;delays in new product launches, (iv)&nbsp;the inability of Astellas to market existing and new products effectively, (v)&nbsp;the inability of
Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi)&nbsp;infringements of Astellas&#146; intellectual property rights by third parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute
an advertisement or medical advice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FibroGen Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding FibroGen&#146;s strategy, future plans, and prospects, including statements regarding the
development of the company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory, and commercial plans, and those of our partners. These
forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;,
&#147;should,&#148; &#147;on track,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words,
although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our
various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended June&nbsp;30, 2018, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except
as required by law.</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>### </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts for inquiries or additional information: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEL: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+81-3-3244-3201</FONT></FONT> FAX: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">+81-3-5201-7473</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g646661g71e91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g646661g71e91.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8Z!\TWE-$H4L9'V@#MZFA(F4K6):104 % !0 4 % !0 4 % !0 4 % !0 4
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M("4@C:1@.I &::5W8-CST?&?0R,_8;W\E_QK7V,C/VB#_A<^A_\ /C>_DO\
MC1[&0>T1J^'?B5I?B368M,M;6YCED5F#2 8X&>QI2IN*N-33=B:'XCZ%/XF&
MAHTWG&3R5EVCRR_3&<YZ\=*7LY)7'S*]A_BOQ[IWA&[@M[RWGE:9"X,0&  <
M=S1"FY; Y*)U$,HF@CE4$!U# 'W%9[%#Z "@ H * "@ H * ,O7/$.F>'++[
M5J5R(E/"*.6<^@'>JC%RT0FTCSJ[^-D*RD6>C.T8/#2R@$_@!Q6RH]V9^T+^
MD?&32KN98M2LY;+)QYH;S%'U[C]:3HM;#51=3T:">*Y@2>"19(G&Y74Y!'J#
M6&QH24 % !0 4 % !0 4 % %:Z692L\&69!S'GAQ_C30C(U"[CMI;#49+P!2
MQB(1<,5;'0<Y(8+],FJ2Z$6?5F8L-[XBOGABFDM;2W9O,>0*SESQ@#& 0/7I
MFKNHHY5#VM2S>B_/_AC0'@K34@"123HZ_=?<"%/J%(V@^X -3[1]33ZM%? V
MO3_+8HJ=0T+4X[6]EFN8+B3S(YH@H)8 [LKCKWX]ZK22T,W[6FUSZKNO\C1T
MF[26SN=1CO499YBY&S<P'W4&,]P <>]3)6=K%8>7.G.,MW_P%^!JVD,A8W-P
M/WS# 7^XOH/Z_P#UJA]CK1#X@_Y%S4_^O63_ -!-..Z!['AGPQ\/:;XCUJZM
MM3A,L4=MO4!BN#N4=OK755DXK0Q@DWJ>I?\ "K?"?_0/?_O\W^-<_M9&G(B]
MI'@3P_H6HI?Z?:-'<(" QD8\$8/!-)SDU9C44MCF+72/ Z?$/S(KUSJBW!(M
M.=@E'.>GX]:T;GR>1-H\QSOQL_Y#>G?]>S?^A5=#9DU-STB\\8:%X>L;6/4;
M]$F\E#Y2_,_0=A6"A*3T-.9(72/'GAS6IU@M-143M]V.4%&/TS0Z<H[@I)FY
M>WMOIUE->7<HBMX5W.YZ*/6I2OHBMC(7QMX<;2Y=275(C:Q/Y;/S][&< =SB
MJY)7M8GF6Y%H7CK0O$5\;+3KB1IPI;:\17(%$J<HJ[!23V)-7\;^'M$G,%[J
M48G7K&GS,/KBA0D]@<D@TCQMX>UN<066I1F<](W^5C],T.$H[@I)FW<3QVMM
M+<2G;'$I=CZ "H6I1\ZS3:E\1O&JH'(,[D1@_=AB'_UOUKMTIQ.?63/9M(^'
MOAO2;58O[-BNI /FEN%#EC]#P/PKF=23-E%(P_%WPLT[4K1I]#A2SOEY$8.(
MY/8CL?<54*K6Y,H)['2^#?#C^%] CL)+M[A\[VS]U2>H7VJ)RYG<J*LK%S6?
M$6DZ!$)-3O8X-WW5)RS?0=:48N6PVTMSGH/BKX3FF$?VR6//\4D+!?SJ_921
M/.CK[2[M[ZV2YM9DFA<95T.0:S:MN69EOXKT6ZUI]'AOD:_1F4Q8.05&3_*G
MR-*XKJ]BC??$+POI]T;:;5(VD4X;RP6"GZBFJ<GT%S)&WINJV&KV@NM/NH[F
M$\;D.<?7TJ6FM&-.^Q<I#(IH$G"[L@J<JRG!!IIV)E%2W,JZEUBT148K+#GY
MKF&/=(J_]<^Y]QG_ ':I*+,>:I3^)77=;_=_E]QF3P6307)L9C-#-&?MEQG>
M\?\ M ]F]NW7V+U6Y2G!QYHO0T/" 4^'()=@229FDD &/F+'_ 45/B(PRM3N
M]WK]YNUF=)S_ (S53X?9AGSDD5HBHRP;N1[[=U:4_B.?$MJG9;O0I(E@_D-=
MEH94C LS ,22KV8 =3C'RXX_'AW?0'1@[=&NQJVMUJUO&&O+0S0D\,F/-4>K
M*.#_ ,!/X5+47L"E5A\2NOQ^[_+[A^M3Q3^&=4:)PP%M(#['8:25I(U4E)71
M\\^$O%5WX3OI;NSMXIGEB\LB4' &0>Q]J[)P4E9F47RG7?\ "Y]<_P"@99?D
M_P#C6?L5W*]HSJ_ /C[4?%FKW-G>6=O D4'F Q!LD[@.Y]ZSJ4U%71<9-LXN
MQ_Y+FW_7_)_Z":T?\,A?&6OC5_R'=-_Z]V_]"I4=F%3<T/"'PRM]9TV/6?$,
M\\LMV/,6)7V_*>A8]<_RI3JV=HCC"^K,SQ_\.+?P[IXU;2)93;HP$L3G)3/1
M@?2JIU.9V8I0MJC>LM>GU[X+:J]TY>YMH7@=SU; !!/X$?E4./+45BD[Q.+\
M >#/^$NN)Q=7,D.GVQ!81]6<]AG@<#DUK4GR;$1C<[3Q%IFG?#3PU=W&BF5;
MZ_*P)+(VYD')./PK*+=1ZEM*"T,;P#\.;7Q!IO\ ;.LR2M%,Q\J)6P7P<%F/
M7K55*CB[(F,+ZL/'WPXMO#^G?VQHLDJPQ,/-B=LE,GAE/7K13J<SLPE"VJ-K
M3_$=QK_P=U>2X<O>6L#PR/W88R&_(_I4N/+412=XG._!E8SXJNRV/,%J=GTW
M#/\ 2KK?"33W/<JY38\8G^,NKQ7$L8TNTPCE03O[''K73[%=S'VC.O\ !GCJ
MX\0Z+JVHWUK%"M@-V(B?F&TL>OTK.<.5I(N,KH\KTO[-XR\63WOB75X[2W.7
M9I) I(SPBYZ?X"MW[D;11DO>>IW%WX:^&$]FT4&JVMM+CY95O<D'UP3@UDI5
M%T+M R/A1JTVG>*[G0?M"SVDV_85;*;E_B7V(JZJO&XH.SL<WJMI>7_Q+U"R
ML)&CN+B]DB5@2,!B0<X[8)S[5::4+LEZR/2T^#GA];#R7GNFN=O,X?'/KMZ8
M]JP]M*YI[-'$^#Y[SP=\2?['DES')-]FE X5\_=;^1K6=IPN1'W96/>JY#<*
M *MU<.C+!  9W&1GHH_O&FA&%JVGV\EO#;I;SQ7-U((FF! 9UZONP>?E#=?6
MM(MK4X<1",TDDTWI_G^!3L[V;PU=SQRQ27-G/(SYBB(:-QU^7I@C!X]*;2D.
M%2=/1JZ\M_N-IO%6C(,-=D2[=WE&-@^/]W&:CDD;QQ%.3LGKV,::XN/$FIV[
M>5-:6=I+PKI^\=RIZCH,#^=6ERHP<U4JI](_G_P"]I5C!!#-9QVTJ7%O+M6<
MX+!>J'.<X .,=.#4-]3J3Z6-RUN#*&CD79/'PZ_U'L:EFA5U\ >'-4P/^763
M_P!!-..Z$]CQWX-V\-QXBO5GA251:9 =00/G7UKHK:(RI[GM/]EZ?_SXV_\
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M+_$AX5_\#[U-^AT6ZEM22H)4J2.A[4ABT % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%;P"WA";BQR2S'JQ/4
MTV[DQCRJQ+2*"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
.. "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g646661g98y34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g646661g98y34.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MR^*^MVY N8;>Y4?[)4_F*:FT<U3(L/+X&U^)T^G_ !9TJ;"WMK-;'NR_./\
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M72 * "@ H 0@,I!Z'B@!L44<,8CB141>@48 H ?0 4 % !0!2DT?399C*]C
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8'Y4 01Z+ID+ADL( PZ'8.* +W3@4 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
